Voltage-gated sodium channels (VGSCs) play an important role in neuronal excitability. Regulation of VGSC activity is a complex phenomenon that occurs at multiple levels in the cell, including transcriptional regulation, post-translational modification and membrane insertion and retrieval. Multiple VGSC subtypes exist that vary in their biophysical and pharmacological properties and tissue distribution. Any alteration of the VGSC subtype profile of a neuron or the mechanisms that regulate VGSC activity can cause significant changes in neuronal excitability. Inflammatory and neuropathic pain states are characterised by alterations in VGSC subtype composition and activity in sensory neurons. This review focuses on the VGSC subtypes involved in such pain states.
Introduction
Voltage-gated Na + channels (VGSCs) are large transmembrane proteins that mediate the rising phase of the action potential in excitable cells. VGSCs consist of an α-subunit which forms a Na + -conducting pore and associated β-subunits that modulate the biophysical properties of the channel. Although it has been known since the late 1940s that movement of Na + across the membrane mediate action potentials in excitable cells, it was not until 1984 that the first VGSC α-subunit was cloned from the electric eel Electrophorus electricus (Noda et al., 1984) . Since then, nine mammalian VGSC α-subunit subtypes have been identified. These vary in their tissue distribution, biophysical properties and their sensitivity to neurotoxins. VGSCs are generally classified as either tetrodotoxin (TTX)-sensitive (TTX-S) or TTX-resistant (TTX-R) (see Table 1 ). Four auxiliary β-subunits of approximately 35 kDa have been identified: β1 (with the variant β1A), β2, β3 and β4 (Wood, Boorman, Okuse, & Baker, 2004) .
The combination of VGSC subtypes expressed in individual cells is a key determinant of the membrane excitability, conduction velocity and possibly in some tissues also the resting membrane potential. Alterations in the activity or expression of VGSCs subtypes leading to hyperexcitability are associated with several disease states such as epilepsy, stroke and pain. In particular, chronic pain states are known to involve alterations of VGSC activity and subtype composition in sensory neurons. This brief review describes the structure, function and regulation of VGSCs with the focus on VGSC subtypes involved in inflammatory and neuropathic pain.
Structure of VGSCs
The VGSC α-subunits of approximately 260 kDa consist of more than 1800 amino acids with four internally homologous domains, each of which contains six membrane-spanning helices (S1-S6) ( Fig. 1) (Noda et al., 1984) . During an action potential, the VGSC transits through at least three states; closed, open and inactivated. Activation of the VGSC is mediated by the S4 helix of each domain, whereas inactivation is mediated by a motif located on the cytoplasmic side of the channel in the intracellular loop that connects domains III and IV. The loop between segment S5 and S6, called the P-loop, is thought to mediate the cation selectivity of the open channel (Catterall, 2000) . VGSC α-and β-subunits interact mainly through their extracellular domains, most likely in the configuration 1α:2β. All β-subunits adopt the immunoglobulin-like fold with an intracellular C-terminus, one membrane-spanning domain and two extracellular β-sheets. β1 and β3 are non-covalently attached to the α-subunit, whereas β2 and β4 are connected via disulfide bonds (Isom, 2001) .
Expression, activation and turnover
Neuronal VGSC expression is modulated by growth factors such as nerve growth factor (NGF) and glial-derived neurotrophic factor (GDNF). These growth factors up-regulate VGSC mRNA levels, often in a subtype-specific manner that depends on the neuronal cell type and growth factor combination (Fjell et al., 1999) . Post-translational regulation is even more complex and also varies between VGSC α-subunit subtypes. Phosphorylation and auxiliary β-subunits can modulate current amplitude as well as the kinetics of transition between the closed, open and inactivated state (Isom, 2001) . Phosphorylation sites for protein kinase A (PKA) and protein kinase C (PKC) are localised in the intracellular loops of the α-subunit (see Fig. 1 ), and in general, phosphorylation increases the current amplitude of TTX-R VGSCs but exerts the opposite effect on TTX-S subtypes (Chahine, Ziane, Vijayaragavan, & Okamura, 2005) . In addition to regulating the biophysical properties of VGSCs, β-subunits also modulate their cell surface levels by anchoring the VGSC to the cytoskeleton (Isom, 2001) . In general, little is known about the regulation of trafficking and turnover of VGSCs, however, certain regulatory pathways involving membrane insertion, stabilisation and retrieval have been described (Fig. 2) . Association with ankyrin, annexin II and contactin stabilise VGSCs in the membrane and may also increase their trafficking to the cell surface (Chahine et al., 2005) . On the other hand, ubiquitin ligases of the Nedd4 family target VGSCs for proteasomal destruction, thus reducing their membrane density (Fotia et al., 2004) .
Biological function of VGSCs in sensory neurons
Of the nine mammalian VGSC subtypes, six are expressed at high levels in sensory neurons (see Table 1 ). Sensory neurons constitute the first link in the somatosensory pathway and include dorsal root ganglion (DRG) neurons, trigeminal ganglion neurons and nodose ganglion neurons. Large DRG neurons (≥35 μm diameter) exhibit fast activating and inactivating TTX-S Na + current and express high levels of Na v 1.1, Na v 1.2 and Na v 1.6. Neurons of intermediate size exhibit both TTX-S and TTX-R Na + currents whereas small neurons (<20 μm diameter) exhibit primarily TTX-R Na + currents. Na v 1.7 is expressed throughout DRG neurons of all sizes (Black et al., 1996) . The two TTX-R Na + channels, Na v 1.8, which produces a slowly inactivating Na + current (Akopian, Sivilotti, & Wood, 1996) and Na v 1.9, which generates a persistent Na + current (Dib-Hajj, Tyrrell, Black, & Waxman) , are located primarily in small DRG neurons, many of which constitute the cell bodies of neurons involved in the transmission of pain stimuli (nociception) (Djouhri et al., 2003) . The activation kinetics of Na v 1.9 are too slow to contribute to the action potential, but given that it exhibits a low threshold of activation ( 20 mV more negative than other VGSCs), it is likely to have a depolarising effect on the resting membrane potential. In contrast, Na v 1.8 exhibits a higher threshold of activation (Akopian et al., 1996) , which explains why small DRG neurons are normally silent. Representative TTX-R (slowly-inactivating and persistent) and TTX-S Na + currents recorded from isolated rat DRG neurons are shown in Fig. 3 .
VGSCs and pain
Pain can be classified as either inflammatory or neuropathic. Inflammatory pain is caused by tissue injury or inflammation and can be relieved with drugs such as non-steroid anti-inflammatory drugs, whereas direct damage to nerves cause neuropathic pain, which is refractory to normal pain regimes. Significantly, both inflammatory and neuropathic pain states are characterised by alterations in VGSC subtype composition and expression in sensory neurons.
Na v 1.8 and Na v 1.7: key players in inflammatory pain
Inflammatory pain states, studied in rodent models injected with inflammatory agents, are characterised by an increase in TTX-R Na + current and a parallel increase in expression of Na v 1.8 in DRG neurons (Akopian et al., 1999) . The increase in Na v 1.8 expression is believed to be attributed to the increased levels of NGF associated with inflammation (Fjell et al., 1999) . Other inflammatory mediators also cause phosphorylation of Na v 1.8, increasing Na + current amplitude. Phosphorylation also causes a hyperpolarising shift in the voltage-dependence of activation and an increase in activation and inactivation rates of Na v 1.8 (Wood et al., 2004 ). An important demonstration of a role of Na v 1.8 in pain arises from studies of Na v 1.8 null mutant mice, which were healthy but exhibited decreased responsiveness to noxious mechanical stimuli and reduced inflammatory-induced hyperalgesia. This indicates that they exhibited attenuated pain behaviour compared to wild-type mice (Akopian et al., 1999) .
The other VGSC subtype with a significant role in inflammatory pain is Na v 1.7. The inflammatory disorder, primary erythermalgia, is associated with mutations in the gene encoding Na v 1.7 (Yang et al., 2004) . A recent study of Na v 1.7 knockout mice demonstrated a more significant role of this VGSC subtype in inflammatory pain than Na v 1.8. Global deletion of Na v 1.7 is lethal, but when this channel is selectively knocked out in nociceptors, mice exhibit reduced or completely abolished pain responses to a range of inflammatory mediators (Nassar et al., 2004) .
Neuropathic pain is typically studied in animal models of sciatic nerve ligation. These models exhibit changes in populations of Na v subtypes expressed in DRG neurons that are almost the opposite of inflammatory pain, that is, a reduction in TTX-R Na + current amplitude and an increase in TTX-S Na + currents (Hains et al., 2003) . The change in Na + current characteristics is accompanied by a decrease in mRNA transcripts for Na v 1.8 and Na v 1.9, most likely due to decreased levels of neurotrophins, and the induction of mRNA for Na v 1.3, which is normally only present in DRG of embryonic rats (Hains et al., 2003) . Na v 1.3 mediates a TTX-S Na + current with rapid kinetics of recovery from inactivation, a property that promotes the characteristics of repetitive firing observed in neuropathic pain (Hains et al., 2003) . The β3 subunit in the DRG is also up-regulated in neuropathic pain models. β3 has been shown to accelerate the recovery from inactivation of Na v 1.3, and is therefore likely to increase repetitive firing (Shah et al., 2000) .
The role of Na v 1.8 in neuropathic pain is contentious. Antisense knockdown of Na v 1.8 has been shown to attenuate neuropathic pain behaviour in rats (Lai et al., 2002) . Furthermore, changes in the spatial distribution of Na v 1.8 from the DRG neuron cell body to the site of injury in the axon have been reported, which may contribute to primary sensitisation (Novakovic et al., 1998) . In contrast, neuropathic pain behaviour develops normally in Na v 1.8 null mutant mice, arguing against a role for this VGSC subtype in neuropathic pain (Akopian et al., 1999) . It was initially thought that the development of neuropathic pain in the Na v 1.8 null mutant mice was due to compensatory up-regulation of Na v 1.7. However, recent studies have shown that both the Na v 1.7 nociceptor-specific knockout and a double Na v 1.7/Na v 1.8 knockout can develop neuropathic pain (Nassar, Levato, Stirling, & Wood, 2005) .
Na v 1.9: a possible role in pain states
Although expressed predominantly in neurons identified as nociceptors, the role of Na v 1.9 in pain states is illdefined. Given the depolarising effect of Na v 1.9 on the resting membrane potential, an up-regulation of Na v 1.9 may shift the membrane potential closer to the activation threshold of other VGSC subtypes, promoting hyperexcitability. Conversely, a down-regulation below normal levels (as observed in neuropathic pain), resulting in a more hyperpolarised resting potential may reduce steady-state inactivation of other VGSCs (Herzog, Cummins, & Waxman, 2001) . Therefore, both up-and down-regulation of Na v 1.9 may affect neuronal excitability of DRG and contribute to different types of pain. Furthermore, G-protein coupled pathways, known to act downstream of inflammatory meditors, up-regulate Na v 1.9, increasing neuronal excitability (Baker, Chandra, Ding, Waxman, & Wood, 2003) .
Conclusions
Regulation of VGSC activity in sensory neurons is highly complex due to the existence of multiple VGSC subtypes and regulatory pathways. While the precise role of each of the Na v subtypes in pain states remains to be elucidated, recent subtype-specific knockout studies have improved our understanding of the pivotal roles of various VGSC subtypes in pain. As a result, there is an increased need to find selective inhibitors/modulators of Na v subtypes as potential therapeutic agents. Alternative therapeutic strategies could include interfering with protein-protein interactions that alter VGSC activity. Thus, the identification of regulatory pathways, such as those involved in insertion and retrieval (turnover), may lead to the development of novel therapeutics targeting neuropathic and inflammatory pain. These strategies may also involve the use of molecular approaches, such as short interfering RNA (siRNA) to specifically silence genes encoding Na v subtypes or their regulatory proteins.
